Nasdaq

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...
The Gazette

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Seeking Alpha

AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...
STAT

Amgen says its cholesterol shot prevented heart problems in a broad population

Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...
Nasdaq

Amgen's Repatha Cuts Cardiovascular Risk By Up To 36% In Phase 3 Trial

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
News Medical

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen (NASDAQ: AMGN) today announced that the Company will discuss the data supporting the Repatha TM (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the ...